Potential associations between HDAC or EZH2 expression and the prognosis of PTCL subtypes have also been investigated and have shown that EZH2 and HDAC1/2 are frequently upregulated in patients with PTCL and that patients with higher EZH2 and HDAC2 expression typically have poorer survival (97). This evidence concerns the gene HDAC2 and mature T-cell and NK-cell non-Hodgkin lymphoma.